Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02710409
Other study ID # JSVCT031
Secondary ID
Status Completed
Phase Phase 3
First received March 12, 2016
Last updated August 30, 2016
Start date January 2016
Est. completion date August 2016

Study information

Verified date August 2016
Source Jiangsu Province Centers for Disease Control and Prevention
Contact n/a
Is FDA regulated No
Health authority China: Food and Drug Administration
Study type Interventional

Clinical Trial Summary

Influenza is an acute respiratory disease caused by influenza viruses. There are three types of the virus including A, B and C. Both type A and type B viruses can cause acute febrile respiratory tract infection, characterized by sudden fever, headache, muscle pain, cough, sore throat, nasal congestion and general malaise. The main transmission of influenza is through those highly contagious aerosol droplets containing influenza virus passed from infected people to susceptible population. Each year in the fall and winter infection of influenza is widespread in various age groups, with high incidence rate. Although influenza is generally a self-limiting disease, but in children, the elderly (especially those above 65 years old and those with chronic heart, lung, kidney, liver, blood or metabolic diseases such as diabetes or other certain diseases) and those with poor immunity function, influenza can easily lead to serious flu complications such as pneumonia, resulting in severe increase of morbidity and mortality.

In order to evaluate safety and immunogenicity of a quadrivalent influenza vaccine produced by Jiangsu Jindike Biotechnology Co., Ltd. a phase III clinical trial is planned to conduct in healthy Chinese subjects aged 3 years and older.


Description:

Subjects will be randomized into three arms- Experimental Group, Active Comparator A and Active Comparator B by the ratio of 2:1:1.


Recruitment information / eligibility

Status Completed
Enrollment 3664
Est. completion date August 2016
Est. primary completion date June 2016
Accepts healthy volunteers Accepts Healthy Volunteers
Gender Both
Age group 3 Years and older
Eligibility Inclusion Criteria:

- Aged 3 years and older

- Healthy subjects judged from medical history and clinical examination

- Subjects themselves or their guardians able to understand and sign the informed consent

- Subjects themselves or their guardians can and will comply with the requirements of the protocol

- Subjects with temperature <=37.0°C on axillary setting

Exclusion Criteria:

- Subject who has a medical or family history of any of the following: allergic history, seizure, epilepsy, brain or mental disease

- Any prior administration of influenza vaccine in last 6 month

- Subject who is allergic to any ingredient of the vaccine

- Female subject aged =18 years with a positive result after urine pregnancy test or during pregnancy or baby nursing period

- Subject with damaged or low immune function which has already been known

- Subject who had a seasonal influenza medical history in last 6 months

- Subject with acute febrile illness or infectious disease

- Major congenital defects or serious chronic illness, including perinatal brain damage

- Thrombocytopenia, blood coagulation disorder or bleeding difficulties with intramuscular injection

- Subject who has serious allergic history

- Subject with other medical history not suitable for vaccination such as fainting during injection

- Any prior administration of immunodepressant or corticosteroids in last 6 months

- Any prior administration of blood products in last 3 months

- Any prior administration of other research medicine/vaccine in last 30 days

- Any prior administration of any attenuated live vaccine in last 30 days

- Any prior administration of subunit or inactivated vaccines in last 14 days, such as pneumococcal vaccine

- Any medical, psychological, social or other condition judged by investigator, that may interfere subject's compliance with the protocol or signature on informed consent

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention


Related Conditions & MeSH terms


Intervention

Biological:
Quadrivalent influenza vaccine
0.5 ml/vial, one dose, intramuscular injection on day 0
Trivalent influenza vaccine A
0.5 ml/vial, one dose, intramuscular injection on day 0
Trivalent influenza vaccine B
0.5 ml/vial, one dose, intramuscular injection on day 0

Locations

Country Name City State
China Guanyun County Center for Disease Control and Prevention Lianyungang Jiangsu

Sponsors (2)

Lead Sponsor Collaborator
Jiangsu Province Centers for Disease Control and Prevention Jiangsu Jindike Biotechnology Co., Ltd.

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary the 95% confidence interval (CI) lower limit for the seroconversion against each corresponding flu strain after vaccination is=40% in subjects aged 3-59 years and=30% in subjects aged =60 years separately Immunogenicity outcomes were assessed in serum samples by Hemagglutination inhibition (HAI) assay. The lowest dilution used in the assay is 1/10. Seroconversion was defined as either a pre-vaccination HAI titer < 1:10 and a post-vaccination titer =1:40 or a pre-vaccination titer =1:10 and = four-fold increase in post-vaccination titer. 28 days after vaccination No
Primary incidence of solicited adverse reactions after vaccination incidence of solicited adverse reactions (including systemic and local adverse reactions) after vaccination 0-7 days after vaccination Yes
Secondary the 95% CI lower limit for the post-vaccination seroprotection rates against each corresponding flu strain is =70% A seroprotected subject is defined as a vaccinated subject with serum HAI titer= 1:40. 28 days after vaccination No
Secondary the post-vaccination mean geometric increases (GMIs) of HAI titer against each corresponding flu strain is=2.5 in subjects aged 3-59 years and=2.0 in subjects aged =60 years separately Hemagglutination inhibition (HI) titers were used to calculate post-vaccination mean geometric increases (GMIs) of each of the influenza vaccines. 28 days after vaccination No
Secondary incidence of unsolicited adverse reactions after vaccination incidence of unsolicited adverse reactions (including systemic and local adverse reactions) after vaccination 0-28 days after vaccination Yes
Secondary incidence of serious adverse event (SAE) after vaccination 0-28 days after vaccination Yes
Secondary incidence of serious adverse event (SAE) after vaccination 29 days to 6 month after vaccination Yes
See also
  Status Clinical Trial Phase
Completed NCT05523089 - The Effectiveness of CD388 to Prevent Flu in an Influenza Challenge Model in Healthy Adults Phase 2
Completed NCT05009251 - Using Explainable AI Risk Predictions to Nudge Influenza Vaccine Uptake N/A
Completed NCT03282240 - Safety and Immunogenicity of High-Dose Quadrivalent Influenza Vaccine in Participants ≥65 Years in the US Phase 3
Completed NCT00968526 - Study to Evaluate Immunogenicity and Safety of an Investigational Influenza Vaccine (H1N1) in Adults Phase 3
Completed NCT00971425 - Evaluation of the Immune Response and the Safety of a Pandemic Influenza Candidate Vaccine (H1N1) Phase 3
Completed NCT00968539 - Study to Evaluate the Immunogenicity & Safety of an Investigational Influenza Vaccine (H1N1) in Adults Phase 3
Completed NCT05525494 - Patient Portal Flu Vaccine Reminders (5) N/A
Completed NCT04074928 - Safety and Immunogenicity Study of QIVc in Healthy Pediatric Subjects Phase 3
Completed NCT04695717 - This Study Was Conducted to Evaluate the Safety and Immunogenicity of IVACFLU-S Produced in Children From 6 Months to Under 18 Years Old and the Elderly Over 60 Years Old in Vietnam Phase 3
Completed NCT05012163 - Lottery Incentive Nudges to Increase Influenza Vaccinations N/A
Completed NCT03888989 - Response to Influenza Vaccine During Pregnancy Phase 1
Completed NCT04109222 - Collection of Serum Samples From Children and Older Adults Receiving the 2019-2020 Formulations of Fluzone® Quadrivalent and Fluzone® High-Dose Influenza Vaccines, Respectively Phase 4
Completed NCT02587221 - Clinical Study to Evaluate the Efficacy, Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Influenza Vaccine Compared to Non-influenza Vaccine Comparator in Adults ≥ 65 Years of Age Phase 3
Completed NCT03453801 - The Role of CD4+ Memory Phenotype, Memory, and Effector T Cells in Vaccination and Infection Phase 1
Completed NCT01440387 - A Study of Immunogenicity and Safety of GSK Biologicals' Influenza Vaccine FLU-Q-QIV in Adults Aged 18 Years and Older Phase 3
Terminated NCT01195779 - Trial to Evaluate Safety and Immunogenicity of GSK Biologicals' Influenza Vaccine GSK2584786A in Healthy Children Phase 2
Completed NCT03321968 - Lot-to-lot Consistency of a Plant-Derived Quadrivalent Virus-Like Particles Influenza Vaccine in Healthy Adults Phase 3
Completed NCT00972517 - Study to Evaluate the Immunogenicity and Safety of an Investigational Influenza Vaccine (H1N1) in Children Phase 3
Completed NCT04570904 - Broadening Our Understanding of Early Versus Late Influenza Vaccine Effectiveness
Recruiting NCT03331991 - Prevention of Influenza and Other Wintertime Respiratory Viruses Among Healthcare Professionals in Israel N/A